Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Y. Chen et al.|Annals of Oncology|2019Cited by 475
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, Yi‐Long Wu et al.|Annals of Oncology|2015Cited by 467
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G. Chen, Changxuan You, J. Feng et al.|Annals of Oncology|2013Cited by 120
Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinomaJin Liu, Ying Huang, J. Feng|OncoTargets and Therapy|2013Cited by 68